|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
102,230,000 |
Market
Cap: |
10.87(M) |
Last
Volume: |
10,264,973 |
Avg
Vol: |
10,236,459 |
52
Week Range: |
$0.1063 - $1.64 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. Co. is also developing several preclinical programs, including SLS-004, SLS-006, and SLS-007 for the potential treatment of Parkinson's Disease, SLS-010 in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
158,757 |
158,757 |
209,757 |
Total Buy Value |
$0 |
$200,222 |
$200,222 |
$230,976 |
Total People Bought |
0 |
2 |
2 |
4 |
Total Buy Transactions |
0 |
2 |
2 |
4 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Golembiewski Michael Joseph |
Chief Financial Officer |
|
2024-02-29 |
4 |
A |
$1.10 |
$457 |
D/D |
417 |
86,869 |
|
- |
|
Mehra Raj |
See Remarks |
|
2023-12-01 |
4 |
B |
$1.32 |
$99,999 |
D/D |
75,757 |
185,142 |
2.81 |
- |
|
Golembiewski Michael Joseph |
Chief Financial Officer |
|
2023-11-30 |
4 |
B |
$1.21 |
$100,223 |
D/D |
83,000 |
86,450 |
2.74 |
- |
|
Golembiewski Michael Joseph |
Chief Financial Officer |
|
2023-02-28 |
4 |
A |
$0.67 |
$8,400 |
D/D |
12,500 |
90,987 |
|
- |
|
O'connor Daniel |
Director |
|
2022-06-01 |
4 |
B |
$0.61 |
$9,789 |
D/D |
16,000 |
16,000 |
2.39 |
55% |
|
Dalesandro Margaret |
Director |
|
2022-05-26 |
4 |
B |
$0.60 |
$20,965 |
D/D |
35,000 |
35,000 |
2.39 |
82% |
|
Mehra Raj |
See Remarks |
|
2022-03-31 |
4 |
B |
$0.85 |
$56,840 |
D/D |
66,667 |
3,281,546 |
2.81 |
11% |
|
Golembiewski Michael Joseph |
Chief Financial Officer |
|
2022-02-28 |
4 |
A |
$0.90 |
$11,263 |
D/D |
12,500 |
78,487 |
|
- |
|
Golembiewski Michael Joseph |
Chief Financial OfficerOfficer |
|
2021-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
65,987 |
|
-32% |
|
Mehra Raj |
See Remarks |
|
2020-02-13 |
4 |
B |
$0.75 |
$100,000 |
D/D |
133,333 |
3,214,879 |
3.23 |
51% |
|
Mehra Raj |
See Remarks |
|
2019-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,081,546 |
3,081,546 |
|
- |
|
Pascoe Richard W |
CEO & Secretary |
|
2019-01-23 |
4 |
D |
$0.23 |
$10,149 |
D/D |
(44,810) |
155,396 |
|
- |
|
Morton Neil |
SVP, Chief Business Officer |
|
2019-01-23 |
4 |
D |
$0.23 |
$7,408 |
D/D |
(32,705) |
100,158 |
|
- |
|
Pascoe Richard W |
CEO & Secretary |
|
2018-11-30 |
4 |
D |
$0.31 |
$5,291 |
D/D |
(17,290) |
200,206 |
|
- |
|
Morton Neil |
SVP, Chief Business Officer |
|
2018-11-30 |
4 |
D |
$0.31 |
$3,968 |
D/D |
(12,968) |
132,863 |
|
- |
|
Dorsey Brian |
Former SVP, Chief Dev Officer |
|
2018-08-30 |
4 |
D |
$0.33 |
$14,264 |
D/D |
(43,225) |
115,891 |
|
- |
|
Dorsey Brian |
Former SVP, Chief Dev Officer |
|
2018-08-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
81,775 |
159,116 |
|
- |
|
Morton Neil |
SVP, Chief Business Officer |
|
2018-01-01 |
4 |
D |
$1.84 |
$4,037 |
D/D |
(2,194) |
145,831 |
|
- |
|
Dorsey Brian |
SVP, Chief Development Officer |
|
2018-01-01 |
4 |
D |
$1.84 |
$10,092 |
D/D |
(5,485) |
159,116 |
|
- |
|
Pascoe Richard W |
CEO & Secretary |
|
2018-01-01 |
4 |
D |
$1.84 |
$14,129 |
D/D |
(7,679) |
217,496 |
|
- |
|
Morton Neil |
SVP, Chief Business Officer |
|
2017-09-05 |
4 |
D |
$1.56 |
$21,985 |
D/D |
(14,093) |
148,025 |
|
- |
|
Pascoe Richard W |
CEO & Secretary |
|
2017-09-05 |
4 |
D |
$1.56 |
$29,312 |
D/D |
(18,790) |
225,175 |
|
- |
|
Dorsey Brian |
SVP, Chief Development Officer |
|
2017-09-05 |
4 |
D |
$1.56 |
$21,985 |
D/D |
(14,093) |
164,601 |
|
- |
|
Sarissa Capital Offshore Master Fund Lp |
10% Owner |
|
2017-08-31 |
4 |
B |
$1.63 |
$9,950 |
I/I |
6,104 |
1,447,906 |
1.5 |
- |
|
Morton Neil |
SVP, Chief Business Officer |
|
2017-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
162,118 |
|
- |
|
395 Records found
|
|
Page 1 of 16 |
|
|